Overview

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Alpha Biopharma (Jiangsu) Co., Ltd.

Treatments:

Erlotinib Hydrochloride
Gefitinib